Literature DB >> 22003216

Apparent dexmedetomidine-induced polyuric syndrome in an achondroplastic patient undergoing posterior spinal fusion.

Allison Greening1, Letha Mathews, James Blair.   

Abstract

A 40-year-old achondroplastic patient underwent posterior spinal fusion under general endotracheal anesthesia. Anesthesia was maintained with isoflurane, and sufentanil, dexmedetomidine, and lidocaine infusions. Urine output increased from 150 mL/hr to 950 mL/hr the fourth hour. An increasing serum sodium, low urine-specific gravity, and increased serum osmolarity occurred simultaneously with the polyuria. Within 2 hours of discontinuing the dexmedetomidine infusion urine output greatly decreased. Within 24 hours all signs of the polyuric syndrome resolved spontaneously. Alpha(2) agonists block arginine-vasopressin release and action; however, a polyuric syndrome has not been reported in the human literature.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22003216     DOI: 10.1213/ANE.0b013e31823299c1

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  One case with dexmedetomidine-induced stuporous state in epileptic patient undergoing abdominal surgery.

Authors:  Dong-Ji Han; Zhi-Gang He; Zhi-Qiang Zhou; Li Feng; Cheng Liu; Yan Xiang; Hong-Bing Xiang
Journal:  Am J Neurodegener Dis       Date:  2017-07-25

2.  Dexmedetomidine-related polyuria in a pediatric patient.

Authors:  Phillip S Adams; Antonio Cassara
Journal:  J Anesth       Date:  2015-11-23       Impact factor: 2.078

3.  Intraoperative Dexmedetomidine-Induced Polyuric Syndrome.

Authors:  Shannon Granger; David Ninan
Journal:  Cureus       Date:  2017-05-03

4.  Unusual adverse effect of dexmedetomidine and its management.

Authors:  Sathishkumar Selvaraj; Sakthirajan Panneerselvam
Journal:  Indian J Anaesth       Date:  2018-04

5.  Intraoperative dexmedetomidine-induced polyuria from a loading dose: a case report.

Authors:  Zhang Chen; Ting Chen; Haiwang Ye; Junping Chen; Bo Lu
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.